Martin Stanulla

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4231608/publications.pdf

Version: 2024-02-01

216 papers	12,056 citations	28274 55 h-index	28297 105 g-index
221 all docs	221 docs citations	221 times ranked	16726 citing authors

#	Article	IF	Citations
1	Can Machine Learning Models Predict Asparaginase-associated Pancreatitis in Childhood Acute Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology, 2022, 44, e628-e636.	0.6	4
2	Environmental Risk Factors for Childhood Acute Lymphoblastic Leukemia: An Umbrella Review. Cancers, 2022, 14, 382.	3.7	23
3	Detection of Cancer Mutations by Urine Liquid Biopsy as a Potential Tool in the Clinical Management of Bladder Cancer Patients. Cancers, 2022, 14, 969.	3.7	2
4	High BMP4 expression in low/intermediate risk BCP-ALL identifies children with poor outcome. Blood, 2022, , .	1.4	0
5	Characteristics of white blood cell count in acute lymphoblastic leukemia: A COST LEGEND phenotypeâ€“genotype study. Pediatric Blood and Cancer, 2022, 69, e29582.	1.5	1
6	Pediatric T-ALL type-1 and type-2 relapses develop along distinct pathways of clonal evolution. Leukemia, 2022, 36, 1759-1768.	7.2	4
7	Venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies by augmenting tumor cell phagocytosis. Blood Advances, 2022, 6, 4847-4858.	5.2	3
8	Frequency and prognostic impact of ZEB2 H1038 and Q1072 mutations in childhood B-other acute lymphoblastic leukemia. Haematologica, 2021, 106, 886-890.	3.5	9
9	Clinical and genetic characteristics of children with acute lymphoblastic leukemia and Liâ€“Fraumeni syndrome. Leukemia, 2021, 35, 1475-1479.	7.2	17
10	Hepatic sinusoidal obstruction syndrome and short-term application of 6-thioguanine in pediatric acute lymphoblastic leukemia. Leukemia, 2021, 35, 2650-2657.	7.2	13
11	The Clinical Utility of Optical Genome Mapping for the Assessment of Genomic Aberrations in Acute Lymphoblastic Leukemia. Cancers, 2021, 13, 4388.	3.7	37
12	Genetic Variation in ABCC4 and CFTR and Acute Pancreatitis during Treatment of Pediatric Acute Lymphoblastic Leukemia. Journal of Clinical Medicine, 2021, 10, 4815.	2.4	2
13	Transcriptional and Mutational Profiling of B-Other Acute Lymphoblastic Leukemia for Improved Diagnostics. Cancers, 2021, 13, 5653.	3.7	10
14	TP53 and KRAS Variants at Initial Diagnosis Identify an Ultra-High Risk Group of Pediatric T-Lymphoblastic Leukemia (T-ALL). Blood, 2021, 138, 1315-1315.	1.4	0
15	Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols. Haematologica, 2020, 105, 1887-1894.	3.5	33
16	TNFR2 is required for RIP1-dependent cell death in human leukemia. Blood Advances, 2020, 4, 4823-4833.	5.2	8
17	Chromatin accessibility landscape of pediatric Tâ€lymphoblastic leukemia and human Tâ€cell precursors. EMBO Molecular Medicine, 2020, 12, e12104.	6.9	13
18	Exploiting the Therapeutic Interaction of WNT Pathway Activation and Asparaginase for Colorectal Cancer Therapy. Cancer Discovery, 2020, 10, 1690-1705.	9.4	38

#	Article	IF	Citations
19	The hematopoietic stem cell marker VNN2 is associated with chemoresistance in pediatric B-cell precursor ALL. Blood Advances, 2020, 4, 4052-4064.	5.2	5
20	Repurposing anthelmintic agents to eradicate resistant leukemia. Blood Cancer Journal, 2020, 10, 72.	6.2	3
21	Frequency and prognostic impact of <scp>PAX5</scp> p.<scp>P80R</scp> in pediatric acute lymphoblastic leukemia patients treated on an <scp>AIEOPâ€BFM</scp> acute lymphoblastic leukemia protocol. Genes Chromosomes and Cancer, 2020, 59, 667-671.	2.8	16
22	Implementation of RNA sequencing and array CGH in the diagnostic workflow of the AIEOP-BFM ALL 2017 trial on acute lymphoblastic leukemia. Annals of Hematology, 2020, 99, 809-818.	1.8	23
23	Flash survey on severe acute respiratory syndrome coronavirus-2 infections in paediatric patients on anticancer treatment. European Journal of Cancer, 2020, 132, 11-16.	2.8	155
24	IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker?. Blood, 2020, 135, 252-260.	1.4	77
25	Model-Based Simulation of Maintenance Therapy of Childhood Acute Lymphoblastic Leukemia. Frontiers in Physiology, 2020, 11, 217.	2.8	10
26	In Vitro Drug Response Profiling in BCP- and T-ALL Primary Samples Adds a Robust Functional Layer Enabling Optimized Guidance of Individualized Therapy in Relapsed and Refractory Pediatric Acute Leukemia Patients. Blood, 2020, 136, 15-16.	1.4	0
27	The Leukemogenic TCF3-HLF Complex Rewires Enhancers Driving Cellular Identity and Self-Renewal Conferring EP300 Vulnerability. Cancer Cell, 2019, 36, 630-644.e9.	16.8	35
28	Synthetic Lethality of Wnt Pathway Activation and Asparaginase in Drug-Resistant Acute Leukemias. Cancer Cell, 2019, 35, 664-676.e7.	16.8	70
29	Impact of NUDT15 genetics on severe thiopurine-related hematotoxicity in patients with European ancestry. Genetics in Medicine, 2019, 21, 2145-2150.	2.4	72
30	Durable remissions in TCF3-HLF positive acute lymphoblastic leukemia with blinatumomab and stem cell transplantation. Haematologica, 2019, 104, e244-e247.	3.5	52
31	Pediatric ALL relapses after allo-SCT show high individuality, clonal dynamics, selective pressure, and druggable targets. Blood Advances, 2019, 3, 3143-3156.	5.2	4
32	TP53, ETV6 and RUNX1 germline variants in a case series of patients developing secondary neoplasms after treatment for childhood acute lymphoblastic leukemia. Haematologica, 2019, 104, e402-e405.	3.5	6
33	Identification of four novel associations for B-cell acute lymphoblastic leukaemia risk. Nature Communications, 2019, 10, 5348.	12.8	58
34	Trypsin-encoding PRSS1-PRSS2 variations influence the risk of asparaginase-associated pancreatitis in children with acute lymphoblastic leukemia: a Ponte di Legno toxicity working group report. Haematologica, 2019, 104, 556-563.	3.5	36
35	A mathematical model of white blood cell dynamics during maintenance therapy of childhood acute lymphoblastic leukemia. Mathematical Medicine and Biology, 2019, 36, 471-488.	1.2	9
36	Poor Prognosis in Children with ABL-Class Fusion Positive B-Cell Acute Lymphoblastic Leukemia Treated According to AIEOP-BFM Protocols. Blood, 2019, 134, 1351-1351.	1.4	4

#	Article	IF	Citations
37	Identification of New Risk Loci and Regulatory Mechanisms Influencing Genetic Susceptibility to Acute Lymphoblastic Leukaemia. Blood, 2019, 134, 650-650.	1.4	0
38	Inducible Phase Separation of GSK3Î± As a Mechanism for Asparaginase Resistance in Acute Leukemias. Blood, 2019, 134, 169-169.	1.4	0
39	Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia. Cancer Cell, 2018, 33, 937-948.e8.	16.8	142
40	Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia. Nature Communications, 2018, 9, 1340.	12.8	58
41	NGS-based methylation profiling differentiates TCF3-HLF and TCF3-PBX1 positive B-cell acute lymphoblastic leukemia. Epigenomics, 2018, 10, 133-147.	2.1	10
42	Five percent of healthy newborns have an ETV6-RUNX1 fusion as revealed by DNA-based GIPFEL screening. Blood, 2018, 131, 821-826.	1.4	74
43	A study on the predictability of acute lymphoblastic leukaemia response to treatment using a hybrid oncosimulator. Interface Focus, 2018, 8, 20160163.	3.0	4
44	IKZF1^{plus} Defines a New Minimal Residual Diseaseâ€“Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2018, 36, 1240-1249.	1.6	194
45	<scp>PDX</scp> models recapitulate the genetic and epigenetic landscape of pediatric Tâ€cell leukemia. EMBO Molecular Medicine, 2018, 10, .	6.9	38
46	RNA based individualized drug selection in breast cancer patients without patient-matched normal tissue. Oncotarget, 2018, 9, 32362-32372.	1.8	1
47	MAP3K7 is recurrently deleted in pediatric T-lymphoblastic leukemia and affects cell proliferation independently of NF-ºB. BMC Cancer, 2018, 18, 663.	2.6	11
48	Lmo2 expression defines tumor cell identity during Tâ€cell leukemogenesis. EMBO Journal, 2018, 37, .	7.8	32
49	Methotrexate-Associated Toxicity in Children with Down Syndrome and Acute Lymphoblastic Leukemia during Consolidation Therapy with High Dose Methotrexate According to ALL-BFM Treatment Regimen. Blood, 2018, 132, 1378-1378.	1.4	2
50	Longitudinal Multilevel Omic Analysis of Pediatric T-ALL Reveals Distinct Mechanisms for Disease Progression in Type 1 and in Type 2 Relapses. Blood, 2018, 132, 2826-2826.	1.4	0
51	Pediatric T-ALLs Developing into a Type 2 Relapse Originate from Cells That Carry the Potential of Variable Maturation into Subclones with Distinct Chromatin Landscapes. Blood, 2018, 132, 1545-1545.	1.4	0
52	Molecular role of the <scp>PAX</scp> 5â€•<scp>ETV</scp> 6 oncoprotein in promoting Bâ€cell acute lymphoblastic leukemia. EMBO Journal, 2017, 36, 718-735.	7.8	34
53	Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. Blood, 2017, 129, e26-e37.	1.4	195
54	Childhood cancer predisposition syndromesâ€”A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology. American Journal of Medical Genetics, Part A, 2017, 173, 1017-1037.	1.2	200

#	Article	IF	Citations
55	Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E4030-E4039.	7.1	62
56	S100-alarmin-induced innate immune programming protects newborn infants from sepsis. Nature Immunology, 2017, 18, 622-632.	14.5	131
57	Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events. Journal of Physical Education and Sports Management, 2017, 3, a001677.	1.2	14
58	Molecular characterization of acute lymphoblastic leukemia with high CRLF2 gene expression in childhood. Pediatric Blood and Cancer, 2017, 64, e26539.	1.5	26
59	The role of constitutive activation of FMS-related tyrosine kinase-3 and NRas/KRas mutational status in infants with KMT2A -rearranged acute lymphoblastic leukemia. Haematologica, 2017, 102, e438-e442.	3.5	12
60	Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno Toxicity Working Group study. Lancet Oncology, The, 2017, 18, 1238-1248.	10.7	87
61	Tâ€cell acute lymphoblastic leukemia in infants has distinct genetic and epigenetic features compared to childhood cases. Genes Chromosomes and Cancer, 2017, 56, 159-167.	2.8	15
62	Genetic association with B-cell acute lymphoblastic leukemia in allogeneic transplant patients differs by age and sex. Blood Advances, 2017, 1, 1717-1728.	5.2	15
63	Intragenic amplification of PAX5: a novel subgroup in B-cell precursor acute lymphoblastic leukemia?. Blood Advances, 2017, 1, 1473-1477.	5.2	25
64	Abstract 4321: TNF receptor 2 is essential for RIP1-dependent cell death in refractory leukemia. , 2017, , .		0
65	Common Genetic Variants in Trypsin Regulating Genes Are Associated with AsparAginase-Associated Pancreatitis in Children with Acute Lymphoblastic Leukemia: A Ponte Di Legno Toxicity Working Group Study. Blood, 2017, 130, 885-885.	1.4	0
66	TP53, ETV6 and RUNX1 Germline Variants in Patients Developing Secondary Neoplasms after Treatment for Childhood Acute Lymphoblastic Leukemia. Blood, 2017, 130, 884-884.	1.4	1
67	A variant at 9p21.3 functionally implicates CDKN2B in paediatric B-cell precursor acute lymphoblastic leukaemia aetiology. Nature Communications, 2016, 7, 10635.	12.8	44
68	Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000. Blood, 2016, 127, 2101-2112.	1.4	208
69	Characterization of leukemias with ETV6-ABL1 fusion. Haematologica, 2016, 101, 1082-1093.	3.5	66
70	Activation of concurrent apoptosis and necroptosis by SMAC mimetics for the treatment of refractory and relapsed ALL. Science Translational Medicine, 2016, 8, 339ra70.	12.4	92
71	Implications of delayed bone marrow aspirations at the end of treatment induction for risk stratification and outcome in children with acute lymphoblastic leukaemia. British Journal of Haematology, 2016, 173, 742-748.	2.5	2
72	Evaluation of a pediatric liquid formulation to improve 6-mercaptopurine therapy in children. European Journal of Pharmaceutical Sciences, 2016, 83, 1-7.	4.0	9

#	Article	IF	Citations
73	Genetic predisposition to acute lymphoblastic leukemia: Overview on behalf of the I-BFM ALL Host Genetic Variation Working Group. European Journal of Medical Genetics, 2016, 59, 111-115.	1.3	23
74	Genetic alterations in glucocorticoid signaling pathway components are associated with adverse prognosis in children with relapsedETV6/RUNX1-positive acute lymphoblastic leukemia. Leukemia and Lymphoma, 2016, 57, 1163-1173.	1.3	18
75	Germline Genetic Variation in IKZF1 and Predisposition to Childhood Acute Lymphoblastic Leukemia. Blood, 2016, 128, LBA-2-LBA-2.	1.4	3
76	CRLF2 over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia. Oncotarget, 2016, 7, 59260-59272.	1.8	24
77	Abstract 3548:In vivoCRISPR reveals dual activation of apoptosis and necroptosis as means to eradicate drug resistant leukemia. , 2016, , .		0
78	2% of Healthy Newborns Reveal ETV6-RUNX1 Fusion By Genomic Inverse PCR for Exploration of Ligated Breakpoints (GIPFEL). Blood, 2016, 128, 4082-4082.	1.4	0
79	The Combination of MRD and Copy Number Alterations (CNAs) Defines an Ultra-High Risk Group of Children with Primary T-Lymphoblastic Leukemia (T-ALL). Blood, 2016, 128, 2911-2911.	1.4	0
80	Identification of an Ultra High-Risk and Targetable Molecular Signature in Relapsed Pediatric T-ALL. Blood, 2016, 128, 1084-1084.	1.4	0
81	Asparaginase-Associated Pancreatitis in Childhood Acute Lymphoblastic Leukemia: A Ponte Di Legno Toxicity Working Group Report on Clinical Presentation and Outcome. Blood, 2016, 128, 585-585.	1.4	1
82	Mutational Landscape of Pediatric Acute Lymphoblastic Leukemia Relapsing after Allogeneic Stem Cell Transplantation. Blood, 2016, 128, 601-601.	1.4	0
83	Central nervous system acute lymphoblastic leukemia: role of natural killer cells. Blood, 2015, 125, 3420-3431.	1.4	37
84	No association between the presence of killer-cell immunoglobulin-like receptor genes and susceptibility to childhood ALL. Blood, 2015, 125, 3355-3357.	1.4	4
85	The 9p21.3 risk of childhood acute lymphoblastic leukaemia is explained by a rare high-impact variant in CDKN2A. Scientific Reports, 2015, 5, 15065.	3.3	24
86	Childhood acute lymphoblastic leukemia-associated risk-lociIKZF1, ARID5BandCEBPEand risk of pediatric non-Hodgkin lymphoma: a report from the Berlinâ€“Frankfurtâ€“MÃ¼nster Study Group. Leukemia and Lymphoma, 2015, 56, 814-816.	1.3	9
87	Multiplex ligation-dependent probe amplification validates LOH6q analyses and enhances insight into chromosome 6q aberrations in pediatric T-cell lymphoblastic leukemia and lymphoma. Leukemia and Lymphoma, 2015, 56, 1884-1887.	1.3	4
88	Genomics and drug profiling of fatal TCF3-HLFâ˚positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options. Nature Genetics, 2015, 47, 1020-1029.	21.4	190
89	Vy-PER: eliminating false positive detection of virus integration events in next generation sequencing data. Scientific Reports, 2015, 5, 11534.	3.3	42
90	Childhood cancer incidence patterns by race, sex and age for 2000â€“2006: A report from the <scp>S</scp>outh <scp>A</scp>frican <scp>N</scp>ational <scp>C</scp>ancer <scp>R</scp>egistry. International Journal of Cancer, 2015, 136, 2628-2639.	5.1	24

#	Article	IF	Citations
91	Mer tyrosine kinase promotes the survival of t(1;19)-positive acute lymphoblastic leukemia (ALL) in the central nervous system (CNS). Blood, 2015, 125, 820-830.	1.4	49
92	Pediatric T-cell lymphoblastic leukemia evolves into relapse by clonal selection, acquisition of mutations and promoter hypomethylation. Haematologica, 2015, 100, 1442-1450.	3.5	65
93	Constitutive Activation of FLT3 Is a Positive Prognostic Factor in Infants with MLL-Rearranged Acute Lymphoblastic Leukemia. Blood, 2015, 126, 1417-1417.	1.4	1
94	Abstract 493: Drug response profiling to inform individualized treatment approaches in high risk leukemia. , 2015, , .		0
95	Drug Response Profiling to Identify Selective Pharmacological Activity in Drug Resistant ALL. Blood, 2015, 126, 2532-2532.	1.4	0
96	Gene Panel Sequencing of Primary and Relapsed Pediatric T-ALL Shows That Relapse-Specific Mutations Are Diverse and Mostly Non-Recurrent. Blood, 2015, 126, 1428-1428.	1.4	0
97	Characterization of Leukemias with ETV6-ABL1 Fusion. Blood, 2015, 126, 84-84.	1.4	1
98	Activation of Simultaneous Apoptosis and Necroptosis to Eradicate Drug Resistant Leukemia. Blood, 2015, 126, 1283-1283.	1.4	0
99	ecancermedicalscience. Ecancermedicalscience, 2014, 8, 401.	1.1	4
100	Frequent and sex-biased deletion of SLX4IP by illegitimate V(D)J-mediated recombination in childhood acute lymphoblastic leukemia. Human Molecular Genetics, 2014, 23, 590-601.	2.9	13
101	Cooperativity of RUNX1 and CSF3R mutations in severe congenital neutropenia: a unique pathway in myeloid leukemogenesis. Blood, 2014, 123, 2229-2237.	1.4	135
102	High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. Haematologica, 2014, 99, 103-110.	3.5	30
103	IKZF1 status as a prognostic feature in BCR-ABL1â€“positive childhood ALL. Blood, 2014, 123, 1691-1698.	1.4	129
104	The activating STAT5B N642H mutation is a common abnormality in pediatric T-cell acute lymphoblastic leukemia and confers a higher risk of relapse. Haematologica, 2014, 99, e188-e192.	3.5	114
105	A Process-Oriented Methodology for Modelling Cancer Treatment Trial Protocols. Lecture Notes in Computer Science, 2014, , 133-146.	1.3	1
106	CRLF2 over-Expression Is a Poor Prognostic Marker in Children with High Risk T-Cell Acute Lymphoblastic Leukemia. Blood, 2014, 124, 1071-1071.	1.4	2
107	The Strong Prognostic Effect of Concurrent Deletions of IKZF1 and PAX5, CDKN2A, CDKN2B or PAR1 in the Absence of ERG Deletions (IKZF1plus) in Pediatric Acute Lymphoblastic Leukemia Strongly Depends on Minimal Residual Disease Burden after Induction Treatment. Blood, 2014, 124, 131-131.	1.4	4
108	Prognostic Value of Rare IKZF1 deletions in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia: An International Collaborative Study. Blood, 2014, 124, 368-368.	1.4	3

#	Article	IF	Citations
109	Genomic Inverse PCR for Exploration of Ligated Breakpoints (GIPFEL), a New Method to Detect Translocations in Leukemia. PLoS ONE, 2014, 9, e104419.	2.5	12
110	Gipfel â€“ a Novel Method for Unbiased Molecular ETV6-RUNX1 Screening of Healthy Newborns. Blood, 2014, 124, 5340-5340.	1.4	0
111	Analyses of a Pair of Concordant Twins with Infant ALL and Discordant Clinical Outcome Reveals Immunoescape As a Mechanism of Disease Persistence in MLL-Rearranged Leukemia. Blood, 2014, 124, 3791-3791.	1.4	2
112	Refinement of IKZF1 Genomic Status in Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia. Blood, 2014, 124, 3785-3785.	1.4	0
113	Targeted Deep Sequencing of Genetic Alterations Identified By Whole Exome Sequencing Reveals Clonal Evolution in Pediatric T-Lymphoblastic Leukemia. Blood, 2014, 124, 491-491.	1.4	0
114	Second Malignant Neoplasms After Treatment of Childhood Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2013, 31, 2469-2476.	1.6	120
115	Acute B lymphoblastic leukaemiaâ€propagating cells are present at high frequency in diverse lymphoblast populations. EMBO Molecular Medicine, 2013, 5, 38-51.	6.9	80
116	Ikaros (IKZF1) alterations and minimal residual disease at day 15 assessed by flow cytometry predict prognosis of childhood BCR/ABLâ€negative acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2013, 60, 420-427.	1.5	24
117	Aberrant ZNF423 impedes B cell differentiation and is linked to adverse outcome of ETV6-RUNX1 negative B precursor acute lymphoblastic leukemia. Journal of Experimental Medicine, 2013, 210, 2289-2304.	8.5	36
118	Leukemia surfaceome analysis reveals new disease-associated features. Blood, 2013, 121, e149-e159.	1.4	63
119	Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia. Blood, 2013, 121, 5145-5153.	1.4	130
120	Variation at 10p12.2 and 10p14 influences risk of childhood B-cell acute lymphoblastic leukemia and phenotype. Blood, 2013, 122, 3298-3307.	1.4	147
121	IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. Haematologica, 2013, 98, 428-432.	3.5	139
122	NOTCH1 activation clinically antagonizes the unfavorable effect of PTEN inactivation in BFM-treated children with precursor T-cell acute lymphoblastic leukemia. Haematologica, 2013, 98, 928-936.	3.5	81
123	Cooperativity Of RUNX1 and CSF3R Mutations In The Development Of Leukemia In Severe Congenital Neutropenia: A Unique Pathway In Myeloid Leukemogenesis. Blood, 2013, 122, 444-444.	1.4	1
124	Abstract 4597: Stroma-derived Basigin controls survival of leukemia cells through regulation of their redox state.. , 2013, , .		0
125	Whole Exome Sequencing In Relapsed Pediatric T-ALL: Progression Into Relapse Is Characterized By An Increased Number Of Somatic Mutations and a Conservation Of Mutations In Leukemogenic Driver Genes. Blood, 2013, 122, 228-228.	1.4	0
126	Low platelet counts after induction therapy for childhood acute lymphoblastic leukemia are strongly associated with poor early response to treatment as measured by minimal residual disease and are prognostic for treatment outcome. Haematologica, 2012, 97, 402-409.	3.5	22

#	Article	IF	Citations
127	GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia. Blood, 2012, 120, 395-403.	1.4	137
128	Small sizes and indolent evolutionary dynamics challenge the potential role of P2RY8-CRLF2â€“harboring clones as main relapse-driving force in childhood ALL. Blood, 2012, 120, 5134-5142.	1.4	49
129	Treatment outcome of CRLF2-rearranged childhood acute lymphoblastic leukaemia: a comparative analysis of the AIEOP-BFM and UK NCRI-CCLG study groups. British Journal of Haematology, 2012, 158, 772-777.	2.5	39
130	Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia. Haematologica, 2012, 97, 1048-1056.	3.5	57
131	Proteomic Exploration of the Cell Surface Landscape Reveals New Leukemia Associated Features.. Blood, 2012, 120, 2506-2506.	1.4	0
132	Image-Based RNA Interference Screening Identifies Microenvironmental Signals Supporting Primary Acute Lymphoblastic Leukemia Cell Survival.. Blood, 2012, 120, 2348-2348.	1.4	2
133	Gain-of-function mutations in interleukin-7 receptor-Î± (IL7R) in childhood acute lymphoblastic leukemias. Journal of Experimental Medicine, 2011, 208, 901-908.	8.5	307
134	Xenografts of highly resistant leukemia recapitulate the clonal composition of the leukemogenic compartment. Blood, 2011, 118, 1854-1864.	1.4	73
135	Rationale for an international consortium to study inherited genetic susceptibility to childhood acute lymphoblastic leukemia. Haematologica, 2011, 96, 1049-1054.	3.5	36
136	Gain-of-function mutations in interleukin-7 receptor-Î± (IL7R) in childhood acute lymphoblastic leukemias. Journal of Experimental Medicine, 2011, 208, 1333-1333.	8.5	6
137	NOTCH1 Activation Neutralizes the Unfavorable Prognostic Effect of PTEN Mutations in BFM-Treated Children with T-ALL. Blood, 2011, 118, 740-740.	1.4	1
138	Abstract 5330: Leukemia initiating cells are frequent and oligoclonal in de novo resistant ALL. , 2011, , .		0
139	Intermediate-Risk Acute Lymphoblastic Leukemia (ALL) Patients with and without Relapse Differentially Depend on Survival Signals From Microenvironment. Blood, 2011, 118, 752-752.	1.4	2
140	Evidence for Cooperation of Receptor Tyrosine Kinases and Activating NOTCH Mutations to Hyperactivate mTOR in T-Cell Leukemia: A Rationale Basis for Targeted Therapy. Blood, 2011, 118, 1381-1381.	1.4	0
141	High CD45 (PTPRC) Expression Is Associated with An Overall Poor Outcome in Childhood Acute Lymphoblastic Leukemia Treated on the ALL-BFM 2000 Protocol and Exerts An Especially Pronounced Effect in Intermediate Risk Patients. Blood, 2011, 118, 742-742.	1.4	0
142	Repeated Bone Marrow Aspiration At the End of Induction Therapy: Implications for Treatment Stratification in Paediatric Acute Lymphoblastic Leukaemia. Blood, 2011, 118, 756-756.	1.4	0
143	Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood, 2010, 115, 1006-1017.	1.4	305
144	Verification of the susceptibility loci on 7p12.2, 10q21.2, and 14q11.2 in precursor B-cell acute lymphoblastic leukemia of childhood. Blood, 2010, 115, 1765-1767.	1.4	142

#	Article	IF	Citations
145	CD11b is a therapy resistanceâ€“ and minimal residual diseaseâ€“specific marker in precursor B-cell acute lymphoblastic leukemia. Blood, 2010, 115, 3763-3771.	1.4	26
146	Detection of prognostically relevant genetic abnormalities in childhood Bâ€cell precursor acute lymphoblastic leukaemia: recommendations from the Biology and Diagnosis Committee of the International Berlinâ€FrankfÃ¼rtâ€MÃ¼nster study group. British Journal of Haematology, 2010, 151, 132-142.	2.5	108
147	Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk. Nature Genetics, 2010, 42, 492-494.	21.4	248
148	Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in nonâ€“high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol. Blood, 2010, 115, 5393-5397.	1.4	212
149	Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood, 2010, 115, 3206-3214.	1.4	685
150	Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. Journal of Clinical Investigation, 2010, 120, 1310-1323.	8.2	287
151	C20orf94 deletion Is Strongly Associated with TEL/AML1 Rearrangement and Links Illegitimate V(D)J Recombination with Gender Bias In Childhood Acute Lymphoblastic Leukemia. Blood, 2010, 116, 1718-1718.	1.4	1
152	In Acute Lymphoblastic Leukaemia, Stemness Is Frequent and Ubiquitous. Blood, 2010, 116, 92-92.	1.4	1
153	Bridging the gap between the north and south of the world: the case of treatment response in childhood acute lymphoblastic leukemia. Haematologica, 2009, 94, 748-752.	3.5	7
154	Genetic polymorphisms of the lymphotoxin alpha gene are associated with increased risk for lethal infections during induction therapy for childhood acute leukemia: a case-control study. International Journal of Hematology, 2009, 89, 584-591.	1.6	10
155	Quantification of free total plasma DNA and minimal residual disease detection in the plasma of children with acute lymphoblastic leukemia. Annals of Hematology, 2009, 88, 897-905.	1.8	31
156	NAMPT is essential for the G-CSFâ€“induced myeloid differentiation via a NAD+â€“sirtuin-1â€“dependent pathway. Nature Medicine, 2009, 15, 151-158.	30.7	195
157	Treatment of Childhood Acute Lymphoblastic Leukemia. Seminars in Hematology, 2009, 46, 52-63.	3.4	148
158	High-resolution genomic profiling of childhood T-ALL reveals frequent copy-number alterations affecting the TGF-Î² and PI3K-AKT pathways and deletions at 6q15-16.1 as a genomic marker for unfavorable early treatment response. Blood, 2009, 114, 1053-1062.	1.4	105
159	Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-MÃ¼nster protocols. Blood, 2009, 114, 1314-1318.	1.4	42
160	Very Early/Early Relapses of ALL Show Unexpected Changes of Clonal Markers and High Heterogeneity in Initial and Relapse Treatment Response: ALL-BFM 2000 and ALL-REZ BFM 96/2002.. Blood, 2009, 114, 2612-2612.	1.4	1
161	Initial leukemic gene expression profiles of patients with poor in vivo prednisone response are similar to those of blasts persisting under prednisone treatment in childhood acute lymphoblastic leukemia. Annals of Hematology, 2008, 87, 709-716.	1.8	23
162	Copy number alterations in childhood acute lymphoblastic leukemia and their association with minimal residual disease. Genes Chromosomes and Cancer, 2008, 47, 471-480.	2.8	21

#	Article	IF	Citations
163	Misconceptions, Challenges, Uncertainty, and Progress in Guideline Recommendations. Seminars in Hematology, 2008, 45, 167-175.	3.4	17
164	Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet, The, 2008, 372, 1484-1492.	13.7	318
165	Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray. Blood, 2008, 111, 776-784.	1.4	191
166	Cloning of genes involved in chromosomal translocations by high-resolution single nucleotide polymorphism genomic microarray. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 11921-11926.	7.1	62
167	Anemia and survival in childhood acute lymphoblastic leukemia. Haematologica, 2008, 93, 1652-1657.	3.5	14
168	Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood, 2008, 111, 4477-4489.	1.4	511
169	Thiopurines in the Treatment of Childhood Acute Lymphoblastic Leukemia and Genetic Variants of the Thiopurine S-Methyltransferase Gene. , 2008, , 173-201.		1
170	Early Diagnosis and Molecular-Based Treatment of Very Highly Resistant Acute Lymphoblastic Leukemia in Childhood. Blood, 2008, 112, 754-754.	1.4	2
171	Integrin Alpha M Chain Expression at Diagnosis Is Inversely Correlated with Cytoreduction Rate and Is Consistently Up-Regulated during Therapy in Acute Lymphoblastic Leukemia (ALL). Blood, 2008, 112, 2526-2526.	1.4	0
172	Childhood Acute Lymphoblastic Leukemia: High Genomic Stability from Initial Diagnosis to Early Relapse.. Blood, 2008, 112, 1522-1522.	1.4	0
173	High Interleukin-15 Expression Characterizes Childhood Acute Lymphoblastic Leukemia With Involvement of the CNS. Journal of Clinical Oncology, 2007, 25, 4813-4820.	1.6	91
174	The NQO1 C609T polymorphism is associated with risk of secondary malignant neoplasms after treatment for childhood acute lymphoblastic leukemia: a matched-pair analysis from the ALL-BFM study group. Haematologica, 2007, 92, 1581-1582.	3.5	18
175	Integrating molecular information into treatment of childhood acute lymphoblastic leukemiaâ€"A perspective from the BFM Study Group. Blood Cells, Molecules, and Diseases, 2007, 39, 160-163.	1.4	26
176	A cross-sectional study of self-reported chemical-related sensitivity is associated with gene variants of drug-metabolizing enzymes. Environmental Health, 2007, 6, 6.	4.0	45
177	Prospective Evaluation of MRD-Kinetics in 274 Children with High-Risk ALL Treated in Trial ALL-BFM 2000: Insights into Development of Resistance and Impact on Further Refinement of Treatment Stratification Strategies.. Blood, 2007, 110, 585-585.	1.4	3
178	The Early Treatment Response of the Clinically Challenging Group of Childhood T-ALL without NOTCH1 Mutations Is Signified by a Specific mRNA Gene Profile.. Blood, 2007, 110, 2789-2789.	1.4	0
179	Significance of Copy Number Alterations for Molecular Treatment Response in Childhood Acute Lymphoblastic Leukemia.. Blood, 2007, 110, 1434-1434.	1.4	0
180	Rearrangement and Deletion of the PAX5 Gene in Pediatric Acute B-Cell Lineage Lymphoblastic Leukemia.. Blood, 2007, 110, 981-981.	1.4	2

#	Article	IF	Citations
181	Thioguanine versus mercaptopurine in childhood ALL. Lancet, The, 2006, 368, 1304-1306.	13.7	10
182	Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. Blood, 2006, 108, 1151-1157.	1.4	262
183	LEF-1 is crucial for neutrophil granulocytopoiesis and its expression is severely reduced in congenital neutropenia. Nature Medicine, 2006, 12, 1191-1197.	30.7	182
184	Gene expression profile of the infective murine model for biliary atresia. Pediatric Surgery International, 2006, 22, 84-89.	1.4	41
185	MTHFR 677 (Câ†'T) polymorphism is not relevant for prognosis or therapy-associated toxicity in pediatric NHL: results from 484 patients of multicenter trial NHL-BFM 95. Annals of Hematology, 2006, 85, 291-300.	1.8	55
186	LEF-1 is crucial for neutrophil granulocytopoiesis and its expression is severely reduced in congenital neutropenia. Nature Medicine, 2006, 12, 1191-1197.	30.7	1,015
187	Thiopurine methyltransferase Genotype Is Not a Risk Factor for Secondary Malignant Neoplasias after Treatment for Childhood Acute Lymphoblastic Leukemia on Berlin-Frankfurt-Muenster Protocols.. Blood, 2006, 108, 150-150.	1.4	3
188	LEF-1 Regulates C/EBP Î± Expression and Neutrophil Differentiation in Normal Myelopoiesis and Congenital Neutropenia by a Î²-Catenin Independent Mechanism.. Blood, 2006, 108, 500-500.	1.4	1
189	High Interleukin 15 Expression Characterizes Childhood Acute Lymphoblastic Leukemia with Involvement of the Central Nervous System.. Blood, 2006, 108, 2270-2270.	1.4	0
190	Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia. Blood, 2005, 105, 821-826.	1.4	142
191	Methylenetetrahydrofolate reductase (MTHFR) 677C>T polymorphism and risk of pediatric non-Hodgkin lymphoma in a German study population. Blood, 2005, 105, 906-907.	1.4	10
192	GSTP1 and MDR1 Genotypes and Central Nervous System Relapse in Childhood Acute Lymphoblastic Leukemia. International Journal of Hematology, 2005, 81, 39-44.	1.6	47
193	Heterogeneous expression pattern of pro- and anti-apoptotic factors in myeloid progenitor cells of patients with severe congenital neutropenia treated with granulocyte colony-stimulating factor. British Journal of Haematology, 2005, 129, 275-278.	2.5	19
194	Polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and susceptibility to pediatric acute lymphoblastic leukemia in a German study population. BMC Medical Genetics, 2005, 6, 23.	2.1	65
195	Thiopurine Methyltransferase (<EMPH TYPE="ITAL">TPMT</EMPH>) Genotype and Early Treatment Response to Mercaptopurine in Childhood Acute Lymphoblastic Leukemia. JAMA - Journal of the American Medical Association, 2005, 293, 1485.	7.4	248
196	Tumor Necrosis Factor and Lymphotoxin Alfa Genetic Polymorphisms and Outcome in Pediatric Patients With Non-Hodgkinâ€™s Lymphoma: Results From Berlin-Frankfurt-MÃ¼nster Trial NHL-BFM 95. Journal of Clinical Oncology, 2005, 23, 8414-8421.	1.6	50
197	Pre-B-Cell Colony Enhancing Factor (PBEF) Is a New Cytokine Regulating Myeloid Differentiation in Healthy Individuals and Patients with Severe Congenital Neutropenia (CN).. Blood, 2005, 106, 387-387.	1.4	1
198	LEF-1 Transcription Factor Regulates Proliferation and Differentiation of Myeloid Progenitors in Healthy Individuals and in Patients with Severe Congenital Neutropenia (CN).. Blood, 2005, 106, 390-390.	1.4	1

#	Article	IF	Citations
199	Gain of Chromosome 21 Is Associated with Early Treatment Sensitivity in Childhood Acute Lymphoblastic Leukemia.. Blood, 2005, 106, 1440-1440.	1.4	0
200	Emergence of translocation t(9;11)-positive leukemia during treatment of childhood acute lymphoblastic leukemia. Genes Chromosomes and Cancer, 2004, 41, 291-296.	2.8	11
201	Gene expression patterns associated with recurrent chromosomal translocations in acute lymphoblastic leukemia. Blood, 2004, 103, 1043-1049.	1.4	87
202	Administration of Granulocyte Colony-Stimulating Factor Does Not Restore Defective Expression of bcl-2 and bcl-2-xL in Myeloid Progenitor Cells of Patients with Severe Congenital Neutropenia (Kostmann Syndrome).. Blood, 2004, 104, 1456-1456.	1.4	0
203	Defective Expression of LEF-1 Transcription Factor mRNA and - Protein in Patients with Severe Congenital Neutropenia (Kostmannâ€™S Syndrome).. Blood, 2004, 104, 782-782.	1.4	1
204	Thiopurine Methyltransferase Genotype Modulates Early Treatment Response to 6-Mercaptopurine as Measured by Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia.. Blood, 2004, 104, 321-321.	1.4	7
205	NQO1 C609T polymorphism in distinct entities of pediatric hematologic neoplasms. Haematologica, 2004, 89, 1492-7.	3.5	27
206	Analysis of t(9;11) chromosomal breakpoint sequences in childhood acute leukemia: Almost identicalMLL breakpoints in therapy-related AML after treatment without etoposides. Genes Chromosomes and Cancer, 2003, 36, 393-401.	2.8	70
207	TNF and Lymphotoxin-Î± Polymorphisms in Patients With Severe Chronic Neutropenia. International Journal of Hematology, 2001, 74, 477-478.	1.6	2
208	Tumor necrosis factor and lymphotoxin-alpha genetic polymorphisms and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control study of patients treated with BFM therapy. BMC Hematology, 2001, 1, 2.	2.6	11
209	Polymorphisms within glutathione S-transferase genes and initial response to glucocorticoids in childhood acute lymphoblastic leukaemia. Pharmacogenetics and Genomics, 2000, 10, 715-726.	5.7	109
210	No evidence for a major role of heterozygous deletion 657del5 within the NBS1 gene in the pathogenesis of non-Hodgkin's lymphoma of childhood and adolescence. British Journal of Haematology, 2000, 109, 117-120.	2.5	30
211	Markers of insulin resistance and sex steroid hormone activity in relation to breast cancer risk: a prospective analysis of abdominal adiposity, sebum production, and hirsutism (Italy). Cancer Causes and Control, 2000, 11, 721-730.	1.8	38
212	Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control study. Blood, 2000, 95, 1222-1228.	1.4	176
213	Estrogen Metabolism and Risk of Breast Cancer: A Prospective Study of the 2:16Î±-Hydroxyestrone Ratio in Premenopausal and Postmenopausal Women. Epidemiology, 2000, 11, 635-640.	2.7	239
214	Short-term Storage of Blood Samples and DNA Isolation in Serum Separator Tubes for Application in Epidemiological Studies and Clinical Research. Annals of Epidemiology, 2000, 10, 538-544.	1.9	10
215	Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia. SSRN Electronic Journal, 0, , .	0.4	0
216	Rating the Quality of Evidence and Making Recommendations: A Guide to the Spectrum of Clinical Research. , 0, , 1-9.		0